HCV Among Merck’s Gains With Schering, But Future Moves Still Murky
Executive Summary
As Merck and Schering-Plough await a potential monkey wrench from Johnson & Johnson for their merger, observers are sorting through each company's partnerships for would-be redundancies
You may also be interested in...
HCV Warning For ESAs Could Raise Questions For Pipeline Drugs
Warning on red cell aplasia and anemia for Procrit and Aranesp in hepatitis C patients could have implications for boceprevir and telaprevir.
HCV Warning For ESAs Could Raise Questions For Pipeline Drugs
Warning on red cell aplasia and anemia for Procrit and Aranesp in hepatitis C patients could have implications for boceprevir and telaprevir.
Schering’s Organon Grab Made Merck's Merger Magic Happen
Takeover in 2007 proved no permanent fix for Schering, but it was enough to lure an even bigger deal.